{
    "id": "5c890c3375a4a5d21900000e",
    "question": "Can oleuropein aglycone interfere with amyloid aggregation?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to understand the nature of oleuropein aglycone and its potential interaction with amyloid aggregation. Oleuropein aglycone is a compound found in olive oil and has been studied for its potential health benefits, including its anti-inflammatory and antioxidant properties. Amyloid aggregation is a key feature of neurodegenerative diseases such as Alzheimer's disease, where it contributes to neuronal damage and death. To determine if oleuropein aglycone can interfere with amyloid aggregation, we need to consider the biochemical properties of both compounds and their potential mechanisms of action. Oleuropein aglycone has been shown to have anti-inflammatory and antioxidant properties, which could potentially impact amyloid aggregation. Additionally, oleuropein aglycone has been shown to have a potential role in modulating the activity of certain enzymes involved in amyloid metabolism. Based on this information, it is plausible that oleuropein aglycone could interfere with amyloid aggregation by modulating the activity of enzymes involved in amyloid metabolism or by its anti-inflammatory and antioxidant properties. However, more research is needed to fully understand the mechanisms by which oleuropein aglycone may interact with amyloid aggregation.\", \"answer_choice\": \"A\"}}",
    "snippets": [
        {
            "id": "Neurology_Adams_8485",
            "title": "Neurology_Adams",
            "content": "suggesting that aggregated amyloid is in some way a protective mechanism of cells. It seems most likely that amyloid alone is not solely responsible for Alzheimer disease, particularly in cases of late-life onset. Amyloid may accelerate degeneration of neurons and once dementia is established, there may be little additional accumulation of amyloid."
        },
        {
            "id": "Pharmacology_Katzung_6653",
            "title": "Pharmacology_Katzung",
            "content": "FIGURE 60\u20132 Some processes involved in Alzheimer\u2019s disease. From the left: Mitochondrial dysfunction, possibly involving glucose utilization; synthesis of protein tau and aggregation in filamentous tangles; synthesis of amyloid beta (A\u03b2) and secretion into the extracellular space, where it may interfere with synaptic signaling and accumulates in plaques. (Reproduced, with permission, from Roberson ED, Mucke L: 100 years and counting: Prospects for defeating Alzheimer\u2019s disease. Science 2006;314:781. Reprinted with permission from AAAS.) TABLE 60\u20133 Some potential strategies for the prevention or treatment of Alzheimer\u2019s disease. A\u03b2, amyloid beta; IL, interleukin; PERK, protein kinase RNA-like ER kinase; PPAR-\u03b3, peroxisome proliferator-activated receptor-gamma."
        },
        {
            "id": "Biochemistry_Lippincott_67",
            "title": "Biochemistry_Lippinco",
            "content": "Misfolding of proteins may occur spontaneously or be caused by a mutation in a particular gene, which then produces an altered protein. In addition, some apparently normal proteins can, after abnormal proteolytic cleavage, take on a unique conformation that leads to the spontaneous formation of long, fibrillar protein assemblies consisting of \u03b2-pleated sheets. Accumulation of these insoluble fibrous protein aggregates, called amyloids, has been implicated in neurodegenerative disorders such as Parkinson disease and Alzheimer disease (AD). The dominant component of the amyloid plaque that accumulates in AD is amyloid \u03b2 (A\u03b2), an extracellular peptide containing 40\u201342 amino acid residues. X-ray crystallography and infrared spectroscopy demonstrate a characteristic \u03b2pleated sheet secondary structure in nonbranching fibrils. This peptide, when aggregated in a \u03b2-pleated sheet conformation, is neurotoxic and is the central pathogenic event leading to the cognitive impairment characteristic"
        },
        {
            "id": "Biochemistry_Lippincott_68",
            "title": "Biochemistry_Lippinco",
            "content": "in nonbranching fibrils. This peptide, when aggregated in a \u03b2-pleated sheet conformation, is neurotoxic and is the central pathogenic event leading to the cognitive impairment characteristic of the disease. The A\u03b2 that is deposited in the brain in AD is derived by enzymic cleavages (by secretases) from the larger amyloid precursor protein, a single transmembrane protein expressed on the cell surface in the brain and other tissues (Fig. 2.13). The A\u03b2 peptides aggregate, generating the amyloid that is found in the brain parenchyma and around blood vessels. Most cases of AD are not genetically based, although at least 5% of cases are familial. A second biologic factor involved in the development of AD is the accumulation of neurofibrillary tangles inside neurons. A key component of these tangled fibers is an abnormal form (hyperphosphorylated and insoluble) of the tau (\u03c4) protein, which, in its healthy version, helps in the assembly of the microtubular structure. The defective \u03c4 appears"
        },
        {
            "id": "Neurology_Adams_8481",
            "title": "Neurology_Adams",
            "content": "Several pieces of evidence favor the view that elevation of the levels of A\u03b242 leads to aggregation of amyloid and then to neuronal toxicity. This is currently the most often cited hypothesis for the genesis of the disease. It appears that the diffuse deposition of A\u03b242 precedes the formation of better-defined neurofibrils and plaques."
        },
        {
            "id": "Pathology_Robbins_1089",
            "title": "Pathology_Robbins",
            "content": "http://ebooksmedicine.net Amyloid deposits can occur in a variety of conditions, in each of which the protein composition is different. Although amyloid always has the same morphologic appearance, it is biochemically heterogeneous. In fact, at least 30 different proteins can aggregate to form fibrils with the appearance of amyloid. Regardless of their derivation, all amyloid deposits are composed of nonbranching fibrils, each formed of intertwined polypeptides in a \u03b2 pleated sheet conformation ( Fig. 5.41 ). Approximately 95% of the amyloid material consists of fibril proteins, the remaining 5% being various glycoproteins. The three most common forms of amyloid are the following: AL (amyloid light chain) amyloid is made up of complete immunoglobulin light chains, the amino-terminal fragments of light chains, or both."
        },
        {
            "id": "Biochemistry_Lippincott_66",
            "title": "Biochemistry_Lippinco",
            "content": "VI. PROTEIN MISFOLDING Protein folding is a complex process that can sometimes result in improperly folded molecules. These misfolded proteins are usually tagged and degraded within the cell (see p. 247). However, this quality control system is not perfect, and intracellular or extracellular aggregates of misfolded proteins can accumulate, particularly as individuals age. Deposits of misfolded proteins are associated with a number of diseases. A. Amyloid diseases"
        },
        {
            "id": "Cell_Biology_Alberts_549",
            "title": "Cell_Biology_Alberts",
            "content": "In normal humans, the quality control mechanisms governing proteins gradually decline with age, occasionally permitting normal proteins to form pathological aggregates. The protein aggregates may be released from dead cells and accumulate as amyloid in the extracellular matrix. In extreme cases, the accumulation of such amyloid fibrils in the cell interior can kill the cells and damage tissues. Because the brain is composed of a highly organized collection of nerve cells that cannot regenerate, the brain is especially vulnerable to this sort of cumulative damage. Thus, although amyloid fibrils may form in different tissues, and are known to cause pathologies in several sites in the body, the most severe amyloid pathologies are neurodegenerative diseases. For example, the abnormal formation of highly stable amyloid fibrils is thought to play a central causative role in both Alzheimer\u2019s and Parkinson\u2019s diseases."
        },
        {
            "id": "InternalMed_Harrison_8943",
            "title": "InternalMed_Harrison",
            "content": "protein. AA amyloid is composed of the acute-phase reactant protein serum amyloid A (SAA) and occurs in the setting of chronic inflammatory or infectious diseases; for this reason, this type was formerly known as secondary amyloidosis. A\u03b22M amyloid results from misfolded \u03b22-microglobulin, occurring in individuals with long-standing renal disease who have undergone dialysis, typically for years. A\u03b2, the most common form of localized amyloidosis, is found in the brain of patients with Alzheimer\u2019s disease after abnormal proteolytic processing and aggregation of polypeptides derived from the amyloid precursor protein."
        },
        {
            "id": "InternalMed_Harrison_8947",
            "title": "InternalMed_Harrison",
            "content": "The mechanisms of fibril formation and tissue toxicity remain controversial. The \u201camyloid hypothesis,\u201d as it is currently understood, proposes that precursor proteins undergo a process of reversible unfolding or misfolding; misfolded proteins form oligomeric aggregates, higher-order polymers, and then fibrils that deposit in tissues. Accumulating evidence suggests that the oligomeric intermediates may constitute the most toxic species. Oligomers are more capable than large fibrils of interacting with cells and inducing formation of reactive oxygen species and stress signaling. Ultimately, the fibrillar tissue deposits are likely to interfere with normal organ function. A more sophisticated understanding of the mechanisms leading to amyloid formation and cell and tissue dysfunction will continue to provide new targets for therapies."
        },
        {
            "id": "Neurology_Adams_8484",
            "title": "Neurology_Adams",
            "content": "There is still uncertainty regarding a direct relationship of amyloid deposition to the loss of neurons and brain atrophy in Alzheimer disease. Alternatively, soluble oligomers of A\u03b2 amyloid may be the toxic agents, whereas the emphasis until now has been on the effects of visible assemblies of insoluble amyloid fibrils. Similarly, TDP-43, the product of inadequate functioning of the progranulin gene, is also deposited in neurons and may play a substantial role in the severity of expression of Alzheimer disease; this protein has been implicated in the pathogenesis of frontotemporal dementia and motor neuron disease, both discussed later in the chapter. Others have questioned the amyloid hypothesis and pointed to the imprecise relationship between amyloid deposition and neuronal loss, even suggesting that aggregated amyloid is in some way a protective mechanism of cells. It seems most likely that amyloid alone is not solely responsible for Alzheimer disease, particularly in cases of"
        },
        {
            "id": "InternalMed_Harrison_30209",
            "title": "InternalMed_Harrison",
            "content": "normal brain aging but dominate the picture in AD. Increasing evidence suggests that soluble amyloid species called oligomers may cause cellular dysfunction and represent the early toxic molecule in AD. Eventually, further amyloid polymerization and fibril formation lead to neuritic plaques, which contain a central core of amyloid, proteoglycans, Apo \u03b54, \u03b1-antichymotrypsin, and other proteins. A\u03b2 is a protein of 39\u201342 amino acids that is derived proteolytically from a larger transmembrane protein, amyloid precursor protein (APP), when APP is cleaved by \u03b2 and \u03b3 secretases (Fig. 448-2). The normal Step 1: Cleavage by either \u02dc or \u02db secretase Step 2: Cleavage by \u02dd secretase"
        },
        {
            "id": "InternalMed_Harrison_29694",
            "title": "InternalMed_Harrison",
            "content": "One major scientific question is whether protein aggregates directly contribute to neuronal death or whether they are merely secondary bystanders. A current focus in all the neurodegenerative diseases is on small protein aggregates termed oligomers. These may be the toxic species of \u03b2-amyloid, \u03b1-synuclein, and proteins with expanded polyglutamines such as are associated with Huntington\u2019s disease. Protein aggregates are usually ubiquinated, which targets them for degradation by the 26S component of the proteasome. An inability to degrade protein aggregates could lead to cellular dysfunction, impaired axonal transport, and cell death by apoptotic mechanisms."
        },
        {
            "id": "Biochemistry_Lippincott_81",
            "title": "Biochemistry_Lippinco",
            "content": "A. It is associated with \u03b2-amyloid, an abnormal protein with an altered amino acid sequence. B. It results from accumulation of denatured proteins that have random conformations. C. It is associated with the accumulation of amyloid precursor protein. D. It is associated with the deposition of neurotoxic amyloid \u03b2 peptide aggregates. E. It is an environmentally produced disease not influenced by the genetics of the individual. F. It is caused by the infectious \u03b2-sheet form of a host-cell protein."
        },
        {
            "id": "Pathology_Robbins_1091",
            "title": "Pathology_Robbins",
            "content": "Many other proteins also can deposit as amyloid in a variety of clinical settings. Some of the most clinically important examples are mentioned in the following section. Amyloidosis results from abnormal folding of proteins, which assume a \u03b2 pleated sheet conformation, aggregate, and deposit as fibrils in extracellular tissues. Normally, intracellular misfolded proteins are degraded in proteasomes and extracellular protein aggregates are taken up and degraded by macrophages. In amyloidosis, these quality control mechanisms fail and fibrillar proteins accumulate outside of cells. The proteins that form amyloid fall into two general categories ( Fig. 5.42 ): (1) normal proteins that have an inherent tendency to associate and form fibrils, particularly when produced in increased amounts; and (2) mutant proteins that are prone to mis-folding and aggregation. The mechanisms of deposition of different types of amyloid are discussed next along with classification."
        },
        {
            "id": "Cell_Biology_Alberts_560",
            "title": "Cell_Biology_Alberts",
            "content": "Until recently, those amyloids with useful functions were thought to be either confined to the interior of specialized vesicles or expressed on the exterior of cells, as in Figure 3\u201334. However, new experiments reveal that a large set of low complexity domains can form amyloid fibers that have functional roles in both the cell nucleus and the cell cytoplasm. These domains are normally unstructured and consist of stretches of amino acid sequence that can span hundreds of amino acids, while containing only a small subset of the 20 different amino acids. In contrast to the disease-associated amyloid in Figure 3\u201333, these newly discovered structures are held together by weaker noncovalent bonds and readily dissociate in response to signals\u2014hence their name reversible amyloids. Many proteins with such domains also contain a different set of domains that bind to specific other protein or RNA molecules. Thus, their controlled aggregation"
        },
        {
            "id": "InternalMed_Harrison_29701",
            "title": "InternalMed_Harrison",
            "content": "block \u03b2-amyloid production and/or aggregation, and these agents are being studied in early clinical trials in humans. Another approach under investigation is immunotherapy with antibodies that bind \u03b2-amyloid, tau, or \u03b1-synuclein. These studies have shown efficacy in preventing the spread of amyloid, tau, and \u03b1-synuclein in animal studies, raising hopes that this could lead to effective therapies by blocking neuron-to-neuron propagation. Two large clinical trials of \u03b2-amyloid immunotherapy, however, did not show efficacy, although this therapeutic strategy is still being studied."
        },
        {
            "id": "InternalMed_Harrison_8941",
            "title": "InternalMed_Harrison",
            "content": "erone proteins during the process of synthesis and secretion, to ensure that they achieve correct tertiary conformation and function, and to eliminate proteins that misfold. However, genetic mutation, incorrect processing, and other factors may favor misfolding, with consequent loss of normal protein function and intracellular or extracellular aggregation. Many diseases, ranging from cystic fibrosis to Alzheimer\u2019s disease, are now known to involve protein misfolding. In the amyloidoses, the aggregates are typically extracellular, and the misfolded protein subunits assume a common antiparallel, \u03b2-pleated sheet\u2013rich structural conformation that leads to the formation of higher-order oligomers and then of fibrils with unique staining properties. The term amyloid was coined around 1854 by the pathologist Rudolf Virchow, who thought that these deposits resembled starch (Latin amylum) 719 under the microscope."
        },
        {
            "id": "Cell_Biology_Alberts_556",
            "title": "Cell_Biology_Alberts",
            "content": "Figure 3\u201332 The structure of an amyloid fibril. (A) Schematic diagram of the structure of a amyloid fibril that is formed by the aggregation of a protein. Only the cross-beta spine of an amyloid fibril resembles the structure shown in Figure 3\u201331. (B) A cut-away view of a structure proposed for the amyloid fibril that can be formed in a test tube by the enzyme ribonuclease A, illustrating how the core of the fibril\u2014formed by a short segment\u2014 relates to the rest of the structure. Electron micrograph of amyloid fibrils. (A, from L. Esposito, C. Pedone and L. Vitagliano, Proc. Natl Acad. Sci. USA 103:11533\u201311538, 2006; B, from S. Sambashivan et al., Nature 437:266\u2013269, 2005; C, courtesy of David Eisenberg.) Figure 3\u201333 The special protein aggregates that cause prion diseases."
        },
        {
            "id": "Neurology_Adams_10847",
            "title": "Neurology_Adams",
            "content": "Treatment Two novel approaches, a small molecule, tafamidis, that prevents the aggregation of amyloid fibrils by stabilizing it in a tetrameric form (Coelho et al, 2012) and interfering RNA therapy (RNAi) that reduces the production of mutant amyloid (Coelho et al, 2013) are both promising. Both have shown promise in halting or reversing familial amyloidosis (Adams et al 2018 and Benson et al). Beneficial effects have been shown in some aspects of the neuropathy but it is not clear if these are sustained. Liver transplantation has proved curative of some of the familial amyloid polyneuropathies, but obviously it has no role in the acquired forms. According to Herlenius and colleagues, more than 500 patients at the time of their writing had received liver transplants with a 77 percent rate of survival, equivalent to liver transplantation for other diseases. Problems in Diagnosis of the Chronic Polyneuropathies"
        },
        {
            "id": "Pathology_Robbins_1090",
            "title": "Pathology_Robbins",
            "content": "The three most common forms of amyloid are the following: AL (amyloid light chain) amyloid is made up of complete immunoglobulin light chains, the amino-terminal fragments of light chains, or both. AA (amyloid-associated) amyloid is composed of an 8500dalton protein derived by proteolysis from a larger precursor in the blood called SAA (serum amyloidassociated) protein, which is synthesized in the liver. \u03b2-amyloid protein (A\u03b2) is a 4000-dalton peptide that is derived by proteolysis from a much larger transmembrane glycoprotein, called amyloid precursor protein. Fig. 5.41 Structureofamyloid.(A)Aschematicdiagramofanamyloidfibershowingfourfibrils(therecanbeasmanyassixineachfiber)woundaroundoneanotherwithregularlyspacedbindingoftheCongoreddye.(B)Congoredstainingshowsapple-greenbirefringenceunderpolarizedlight,adiagnosticfeatureofamyloid.(C)Electronmicrographof7.5-to10-nmamyloidfibrils.(From Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. NEnglJMed349:583\u2013596, 2003.)"
        },
        {
            "id": "Neurology_Adams_10694",
            "title": "Neurology_Adams",
            "content": "Treatment of Amyloid Neuropathy The prognosis of primary-acquired amyloidosis and its associated neuropathy has been poor. Attempts at immunomodulation, immunosuppression (which may help the renal disease), or removal of amyloid by plasma exchange have been marginally effective. Another approach has been bone marrow suppression with high doses of melphalan followed by stem cell replacement (previously harvested from the patient). Several such patients have survived for years with marked improvement in the neuropathy. Recently, several small molecules designed to prevent the aggregation of amyloid fibrils have shown benefit in the familial type of amyloid; see further on."
        },
        {
            "id": "Biochemistry_Lippincott_82",
            "title": "Biochemistry_Lippinco",
            "content": "E. It is an environmentally produced disease not influenced by the genetics of the individual. F. It is caused by the infectious \u03b2-sheet form of a host-cell protein. Correct answer = D. Alzheimer disease (AD) is associated with long, fibrillar protein assemblies consisting of \u03b2-pleated sheets found in the brain and elsewhere. The disease is associated with abnormal processing of a normal protein. The accumulated altered protein occurs in a \u03b2-pleated sheet conformation that is neurotoxic. The amyloid \u03b2 that is deposited in the brain in AD is derived by proteolytic cleavages from the larger amyloid precursor protein, a single transmembrane protein expressed on the cell surface in the brain and other tissues. Most cases of AD are sporadic, although at least 5% of cases are familial. Prion diseases, such as Creutzfeldt-Jakob, are caused by the infectious \u03b2-sheet form (PrPSc) of a host-cell protein (PrPC)."
        },
        {
            "id": "InternalMed_Harrison_30640",
            "title": "InternalMed_Harrison",
            "content": "Experimental studies have shown that transgenic mice expressing mutant amyloid precursor protein (APP) develop amyloid plaques containing fibrils composed of the A\u03b2 peptide approximately a year after inoculation with synthetic A\u03b2 peptides polymerized into amyloid fibrils or extracts prepared from the brains of patients with AD. Mutant tau aggregates in transgenic mice and cultured cells can trigger the aggregation of tau into fibrils that resemble those found in neurofibrillary tangles and Pick bodies. Such tangles have been found in AD, FTDs, Pick\u2019s disease, and some cases of posttraumatic brain injury, all of which are likely to be caused by the prion isoforms of A\u03b2 and/or tau."
        },
        {
            "id": "Neurology_Adams_9037",
            "title": "Neurology_Adams",
            "content": "Figure 38-2. Diagram of proteolysis of amyloid precursor protein (APP). When APP is cleaved sequentially by \u03b2 secretase and then secretase, the resulting amyloid protein can be 40 (A\u03b240) or 42 (A\u03b242) amino acids in length. The latter favors the formation of aggregated fibrillary amyloid protein (fibrillogenesis) rather than normal APP degradation. The fibrillary form of amyloid is neurotoxic, a mechanism favored as the cause of cell damage in Alzheimer disease. Formation of A\u03b242 is promoted by mutations, either in the APP gene itself or in the presenilins. In Down syndrome, excess production of APP and its product A\u03b242 is caused by triplication of the long arm of chromosome 21, the location of the APP gene. The Apo E4 allele is associated with inadequate clearance of A\u03b242 and is another mechanism that promotes fibrillogenesis. (Modified by permission from Sisodia SS, St. George\u2013Hyslop PH: \u03b3-Secretase, notch, A\u03b2 and Alzheimer disease: Where do the presenilins fit in? Nat Rev Neurosci"
        },
        {
            "id": "Cell_Biology_Alberts_557",
            "title": "Cell_Biology_Alberts",
            "content": "Figure 3\u201333 The special protein aggregates that cause prion diseases. (A) Schematic illustration of the type of conformational change in the PrP protein (prion protein) that produces material for an amyloid fibril. (B) The self-infectious nature of the protein aggregation that is central to prion diseases. PrP is highly unusual because the misfolded version of the protein, called PrP*, induces the normal PrP protein it contacts to change its conformation, as shown."
        },
        {
            "id": "Biochemistry_Lippincott_69",
            "title": "Biochemistry_Lippinco",
            "content": "fibers is an abnormal form (hyperphosphorylated and insoluble) of the tau (\u03c4) protein, which, in its healthy version, helps in the assembly of the microtubular structure. The defective \u03c4 appears to block the actions of its normal counterpart. [Note: In Parkinson disease, amyloid is formed from \u03b1-synuclein protein.]"
        },
        {
            "id": "Neurology_Adams_8426",
            "title": "Neurology_Adams",
            "content": "It will become clear in the following discussion that the current theme in the study of degenerative diseases is that of aggregation within specific neurons of normal cellular proteins such as amyloid, tau, synuclein, ubiquitin, and huntingtin. In some cases, the protein is overproduced as a result of the simple fact of a triplication or overactivity of its corresponding gene. In other instances, enzymatic cleavage of a normal precursor protein yields a product with physical properties that lead to its aggregation (as happens with amyloid in Alzheimer disease) or, there may be failure of the normal mechanisms of protein removal, resulting in its excess accumulation. As mentioned above, this has resulted in the denomination of groups of diseases by the type of protein aggregate: tauopathy, synucleinopathy, etc. Even this is an uncertain or intermediate classification as it is not known in most cases if the protein is the cause or the result of cellular damage, and in any case, the"
        },
        {
            "id": "Biochemistry_Lippincott_80",
            "title": "Biochemistry_Lippinco",
            "content": "B. It may be found in typical globular proteins. C. It is stabilized by interchain hydrogen bonds. D. It is an example of secondary structure. E. It may be found in supersecondary structures. Correct answer = C. The \u03b2-sheet is stabilized by interchain hydrogen bonds formed between separate polypeptide chains and by intrachain hydrogen bonds formed between regions of a single polypeptide. The \u03b1-helix, however, is stabilized only by intrachain hydrogen bonds. Statements A, B, D, and E are true for both of these secondary structural elements. .4. An 80-year-old man presented with impairment of intellectual function and alterations in behavior. His family reported progressive disorientation and memory loss over the last 6 months. There is no family history of dementia. The patient was tentatively diagnosed with Alzheimer disease (AD). Which one of the following best describes AD? A. It is associated with \u03b2-amyloid, an abnormal protein with an altered amino acid sequence."
        },
        {
            "id": "InternalMed_Harrison_29700",
            "title": "InternalMed_Harrison",
            "content": "Interestingly, in experimental models of Huntington\u2019s disease and cerebellar degeneration, protein aggregates are not well correlated with neuronal death and may be protective. A substantial body of evidence suggests that the mutant proteins with polyglutamine expansions in these diseases bind to transcription factors and that this contributes to disease pathogenesis. In Huntington\u2019s disease, there is dysfunction of the transcriptional co-regulator, PGC-1\u03b1, a key regulator of mitochondrial biogenesis. There is evidence that impaired function of PGC-1\u03b1 is also important in both Parkinson\u2019s disease and AD, making it an attractive target for treatments. Agents that upregulate gene transcription are neuroprotective in animal models of these diseases. A number of compounds have been developed to block \u03b2-amyloid production and/or aggregation, and these agents are being studied in early clinical trials in humans. Another approach under investigation is immunotherapy with antibodies that bind"
        },
        {
            "id": "InternalMed_Harrison_30599",
            "title": "InternalMed_Harrison",
            "content": "completely hydrolyzed under the same conditions (Fig. 453e-2). In the presence of detergent, PrP 27-30 polymerizes into amyloid. Prion rods formed by limited proteolysis and detergent extraction are indistinguishable from the filaments that aggregate to form PrP amyloid plaques in the CNS. Both the rods and the PrP amyloid filaments found in brain tissue exhibit similar ultrastructural morphology and green-gold birefringence after staining with Congo red dye."
        },
        {
            "id": "Cell_Biology_Alberts_741",
            "title": "Cell_Biology_Alberts",
            "content": "Why is amyloid toxic to cells and how does it contribute to neurodegenerative diseases such as Alzheimer\u2019s disease? Which statements are true? explain why or why not. 3\u20131 Each strand in a \u03b2 sheet is a helix with two amino acids per turn. 3\u20132 Intrinsically disordered regions of proteins can be identified using bioinformatic methods to search genes for encoded amino acid sequences that possess high hydrophobicity and low net charge. 3\u20133 Loops of polypeptide that protrude from the surface of a protein often form the binding sites for other molecules. 3\u20134 An enzyme reaches a maximum rate at high substrate concentration because it has a fixed number of active sites where substrate binds. 3\u20135 Higher concentrations of enzyme give rise to a higher turnover number. 3\u20136 Enzymes that undergo cooperative allosteric transitions invariably consist of symmetric assemblies of multiple subunits."
        }
    ],
    "scores": [
        0.03607481864753609,
        0.0357573121346347,
        0.033528428093645486,
        0.033414558588293196,
        0.032092551901348416,
        0.031988599464251345,
        0.03168402265136453,
        0.03131707430987719,
        0.03128739110258836,
        0.029605901766647257,
        0.027495299128899805,
        0.027400446311846717,
        0.025597663299287456,
        0.02557767327114332,
        0.0253883782185669,
        0.025199728029916706,
        0.02507593416684326,
        0.024960636279219992,
        0.024667787857971905,
        0.024326706597000973,
        0.023860932881551437,
        0.02386053602952977,
        0.023614933342516256,
        0.023579780367110684,
        0.023077812926849888,
        0.022970290101455217,
        0.02244062664914646,
        0.021981742828507192,
        0.021682374729139017,
        0.02087251690617075,
        0.019603278176742487,
        0.018614718614718615
    ]
}